Quarterly report pursuant to Section 13 or 15(d)

Loans Receivable (Tables)

v3.23.3
Loans Receivable (Tables)
9 Months Ended
Sep. 30, 2023
Loans Receivable  
Schedules of Loans Receivable

A breakdown of the loans receivable terms and balances are as follows:

Loans receivable

    

September 30, 2023

    

December 31, 2022

Teneo Fund SPVi LLC Note

$

5,911

$

5,911

Pharma EU, LLC Note

1,410

1,410

A&R Note

710

710

SSZ and Elev8 Note

1,002

1,002

Pure Hana Synergy Note

224

224

Little Beach Harvest Note

2,199

Total loans receivable

$

9,257

$

11,456

Less allowance for expected credit losses

(7,902)

(7,237)

Loans receivable, net of expected credit losses

1,355

4,219

Less current portion of loan receivable

(516)

Loans receivable, long-term

$

1,355

$

3,703

Schedule of Analysis of Credit Quality of Loans Receivable

The following tables present an analysis of the credit quality of loans receivable, together with impairment losses recognized based on lifetime CECL reserves:

As of September 30, 2023

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

7,623

(6,268)

$

1,355

Third party guarantee

1,410

(1,410)

No collateral

224

(224)

Net loans receivable

$

9,257

$

(7,902)

$

1,355

As of December 31, 2022

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

9,822

$

(5,915)

$

3,907

Third party guarantee

1,410

(1,098)

312

No collateral

224

(224)

Net loans receivable

$

11,456

$

(7,237)

$

4,219